Biotech vs. Shorts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KewlHand who wrote (339)	1/30/2000 2:24:00 PM
From: Jesse Schulman	Read Replies (2) of 427

Kewl, seems to me the famous CLPA short squeeze is the dog that didn't bark in the night. Longs have been looking for the squeeze since 9, me among them. Maybe some of the sharper up-days were propelled by covering, but the stock has tripled and short interest is as high as ever. Why should the squeeze come now, if it didn't come then? It's nice to see CLPA far less-successfully manipulated than it was, but shorts are still betting on a decline after approval, and my guess is they'll be right. The argument that FAP is too small an indication to be worthwhile has more pungent immediacy than talk about off-label or the rosy future with prostate. Rick's question about which analysts are projecting what sort of revenue hits the nail on the head, since as you know only Janney is following this stock at all. If after approval (knock knock) CLPA gets some decent coverage from analysts who take the effort to understand the story, then the price could go up. Add in some whiz-bang prostate results this spring and the stock could soar. Market timing is definitely not my specialty, but short-to-middlin' term it's hard for me to see an extension of the run. Looks more like a significant pullback first. itss

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next